HMGB1: Functions, Inhibitors and Clinical Significance

$160.00$215.00

Eylem Taskin, PhD – Professor, Physiology, Adiyaman University, Adiyaman, Turkey
Celal Guven, PhD – Associate Professor, Biophysics, Adiyaman University, Adiyaman, Turkey
Salih Tunc Kaya, PhD – Assistant Dr., Biology, Duzce Univeristy, Duzce, Turkey

Series: Life Sciences Research and Development
BISAC:
SCI056000; SCI008000; MED014000
DOI:
10.52305/KNYQ3299

Damage-associated molecular patterns (DAMPs), a term also known as alarmins coined by Walter G. Land, Seong, and Matzinger, are endogenous danger molecules that are released from damaged or dying cells and activate the innate immune system by interacting with pattern recognition receptors (PRRs). One of the most well-known DAMPs is High Mobility Group Box-1 (HMGB1), the name being such due to its very fast movement in gel electrophoresis. Importantly, HMGB1 has been shown to contribute to the pathogenesis of various diseases including myocardial ischemia/reperfusion injury, epilepsy, diabetes, multiple sclerosis, cancer, as well as hepatic steatosis, and fatty liver disease. There are three sections in the book. The first section is named HMGB1 and Cancer, including two chapters. One of the chapters is focused on HMGB1 in cancer therapy and managing COVID-19 infection, as well as multiple sclerosis. The second chapter in the first section is the crosstalk between cancer and myocardial ischemia/reperfusion injury (MIR) through HMGB1 via ferroptotic cell death. The second section is HMGB1 and metabolic interactions, consisting of two chapters. The first chapter is HMGB1 and inflammation in adipose tissue, resulting in insulin resistance and type 2 diabetes. The second chapter in the second section sums up recent data related to HMGB1 and liver injury, e.g., drug-induced liver injury, alcoholic liver disease, non-alcoholic fatty liver disease, viral hepatitis, sepsis, and acute chronic liver failure, hepatocellular death through oxidative stress, inflammatory signaling, and autophagy in hepatocytes. The third section is about HMGB1 and neurodegenerative diseases. The section contains four chapters. The first chapter in the section evaluates HMGB1 and its antagonist in brain disorders, including epilepsy, headache, neuroimmunological disorders, neurodegenerative disorders, and stroke. The second chapter in the third section is about the role of HMGB1 on post-brain injury, including potential mechanisms and therapeutic opportunities as well. The third chapter in the third section evaluates the interaction of HMGB1 and Multiple sclerosis via TLR4/NF-κB signaling pathway, leading to the release of proinflammatory cytokines causing an inflammatory response. The last chapter aims to explain the effects of HMGB1 on epilepsy.

**Order the printed version and SAVE 50% on the e-book with Print+eBook**

Table of Contents

Preface

Section I: HMGB1 and Cancer

Chapter 1. HMGB1-Targeting Herbal Medicinal Plant Extracts for the Phytotherapy of Cancer and Potential Management of COVID-19
Tuba Reçber¹, PhD, Ibrahim Celalettin Haznedaroglu², MD, and Mustafa Çelebier¹, PhD
¹Hacettepe University, Department of Analytical Chemistry, Ankara Turkey
²Hacettepe University, Department of Hematology, Ankara, Turkey

Chapter 2. The Role of Ferroptotic Cell Death-Related HMGB1 in Inflammation Crosstalk with Cancer and Myocardial Ischemia/Reperfusion Injury
Salih Tunc Kaya¹, PhD, Celal Guven², PhD, and Eylem Taskin³, PhD
¹Düzce University, Department of Biology, Düzce, Turkey
²Adiyaman University, Department of Biophysics, Adiyaman, Turkey
³Adiyaman University, Department of Physiology, Adiyaman, Turkey

Section II: HMGB1 and Metabolic Interactions

Chapter 3. The Role of HMGB1 in Adipocyte Dysfunction Linking Obesity and Type 2 Diabetes
Sagar Barge¹ and Narayan Chandra Talukdar¹,²
¹Chemical Biology Lab I, Institute of Advanced Study in Science and Technology, Paschim Boragaon, Assam, India
²Assam Down Town University, Panikhaiti, Guwahati, India

Chapter 4. The Roles of HMGB1 in Liver Injury
Gülsün Memi
Department of Physiology, Adıyaman University School of Medicine, Adıyaman, Turkey

Section III: HMBG1 and Neurodegenerative Diseases

Chapter 5. The Role of HMGB-1 and Its Inhibitors in Brain Disorders
Onur Cagin Gurlek¹, MD, Anisa Dehghani², PhD, and Hulya Karatas¹, MD, PhD
¹Hacettepe University, Institute of Neurological Sciences and Psychiatry, Ankara, Turkey
²Leiden University Medical Centre, Department of Human Genetics, Migraine Research Group, Leiden, Netherlands

Chapter 6. The Roles of HMGB1 Post-Brain Injury: Implications for Injury and Repair
Malik Zaben¹, PhD, Ron Ved¹,² and Susruta Manivannan²
¹The BRAIN Unit, Neuroscience and Mental Health Research Institute, (NMHRI) School of Medicine, Cardiff University, Cardiff, UK
²Department of Neurosurgery, Southampton General Hospital, Southampton, UK

Chapter 7. The Functional Role of HMGB1/TLR4/NF-κB Signalling Pathway in Multiple Sclerosis
Firdevs Uluc¹, MSc, Bihter Gokce Bozat¹, PhD, Seyda Karabork², PhD and Sule Aydın-Turkoglu³, MD
¹Department of Interdisciplinary Neuroscience, Bolu Abant Izzet Baysal University, Bolu, Turkey
²Department of Medical Microbiology, Bolu Abant Izzet Baysal University, Bolu, Turkey
³Department of Neurology, Bolu Abant Izzet Baysal University, Bolu, Turkey

Chapter 8. HMGB1 Related Pathways in Epilepsy
Hayriye Soyturk¹, PhD, Umit Kilic², PhD, Cansu Onal³, PhD, and Aysegül Yildiz⁴, MSc
¹Bolu Abant Izzet Baysal University, Department of Interdisciplinary Neuroscience, Bolu, Turkey
²Duzce University Vocational School of Health Services, Duzce, Turkey
³Bolu Abant Izzet Baysal University, Department of Biology, Bolu, Turkey
⁴Bolu Abant Izzet Baysal University, Department of Physiology, Bolu, Turkey

About the Editors

Index

 


Editor’s ORCID iD

Eylem Taskin0000-0001-8172-4980
Celal Guven 0000-0003-0499-7787
Salih Tunc Kaya 0000-0002-4133-407X